More than 4 years after his acquired brain injury and stroke, a son and his mother travel from Melbourne, Australia to the Institute of Neurological Recovery in Boca Raton, Florida for treatment.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

From Melbourne, Australia to the INR Los Angeles in February 2015. Wonderful to watch!

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Pain after stroke represents an enormous unmet medical need for those who do not adequately respond to conventional treatment. Chronic central post-stroke pain affects countless stroke survivors around the world. This video depicts the presence of chronic central post-stroke pain prior to treatment at the Institute of Neurological Recovery in Boca Raton. Included is a demonstration of allodynia, i.e. pain or discomfort produced by a sensory stimulus, in this case cold, that normally would not provoke discomfort. In many individuals with central post-stroke pain sensory stimuli, such as light touch, that would normally not be noxious, produce extreme discomfort. Some individuals are unable to tolerate normal touch or even showering because of this post-stroke pain condition. This video depicts the rapid response to a single treatment dose administered on May 7, 2015 at the INR PLLC.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label. Please see the Terms of Use. Copyright 2014 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

From NSW in Australia to the INR in Los Angeles, June 2015. Wonderful and amazing to see rapid improvement in vision, within minutes.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of the INR. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.

From the Gold Coast, Australia to the INR Los Angeles, June 2015. What a wonderful attitude and lovely improvement! The final portion of the video depicts the patient speaking with two of the physicians of the Institute of Neurological Recovery, Nancy Kim MD and Edward Tobinick MD at the INR in Los Angeles, describing his sustained improvement through one week.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of the INR. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.

From Maine to the INR PLLC in Boca Raton, Florida, July 2015.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of the INR. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.

From Brazil to the INR PLLC in Boca Raton, Florida, in July 2015, 3.5 years after a severe stroke caused intractable chronic quadriparesis.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of the INR. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.

Immediate improvement in post-stroke aphasia (naming of family members) and restoration of ability to run within minutes of treatment at the INR PLLC in Boca Raton, July 2015, two years after stroke. Sons and wife comment on his rapid and remarkable therapeutic response.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of the INR. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by the INR, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

The story of a husband and wife who traveled from Melbourne, Australia for treatment of Alzheimer’s disease utilizing the revolutionary new treatment invented by Edward Tobinick M.D. at the Institute for Neurological Research® (INR®) in Los Angeles. Before and after video, testing, and interview with the patient’s wife.

Individual results may vary. Continuing maintenance treatment is necessary to maintain the clinical response. Some patients do not respond. For further scientific information, please see:

• Perispinal etanercept: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.
• TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Edward Tobinick MD, H Gross MD, Alan Weinberger MD, Hart Cohen MD. MedGenMed. 2006 Apr 26;8(2):25.
• Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD, H Gross MD. BMC Neurology. 2008 Jul 21;8:27.
• Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration.Edward Tobinick MD, H Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.